Systolic blood pressure reductions with sotagliflozin (LX4211), a dual SGLT1 and SGLT2 inhibitor, are associated with reductions in urinary sodium excretion

Abstract

vs. V; N vs N+V). Table displays main results. All 3 treatments resulted in similar brachial and central systolic BP values. N alone or in combination with V resulted in lower 24-hour and daytime ACRPP values compared to V (by about 11-14%, p<0.001 each). This effect was driven largely by the heart-rate slowing effects of N; stroke work trended higher with N. Variability (standard deviation and coefficient of variation) of ACRPP and heart rate were lower with N and N/V than V. Results in African Americans, the majority subpopulation, were very similar to those of the entire treatment group. We conclude that the rate-slowing effects of nebivolol cause ambulatory cardiac workload to be lower for both N and N/V than V alone. Addition of V to N does not cause additional BP or rate-altering effects compared to N alone. Heart rate variability is also lower with N, either alone or in combination with V. These results were seen in African Americans.